At present, the most promising blood‐based biomarkers for AD with clinical applicability include the tau phosphorylated at threonine 217 (p‐tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), which provide multidimensional information in AD.4, 5. The gene discussed is MAPT; the disease is Alzheimer disease.